Last reviewed · How we verify
placebo tablets and questionaires
This drug is a placebo, having no active pharmacological mechanism.
This drug is a placebo, having no active pharmacological mechanism. Used for Assessment of patient-reported outcomes in cancer patients.
At a glance
| Generic name | placebo tablets and questionaires |
|---|---|
| Sponsor | Memorial Sloan Kettering Cancer Center |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 3 |
Mechanism of action
As a placebo, it does not interact with any biological systems or molecules. It is used as a control in clinical trials to compare the effects of an active treatment.
Approved indications
- Assessment of patient-reported outcomes in cancer patients
Common side effects
- No adverse events expected
Key clinical trials
- Study of Sildenafil Citrate During and After Radiotherapy/Hormone Therapy for Erectile Function Versus Radiotherapy/Hormone Therapy for Prostate Cancer (PHASE3)
- Dronedarone in Pacemakers Patients With Paroxysmal Atrial Fibrillation (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: